In addition, the molecule has already undergone a
phase III
clinical trial during which no toxicity was observed, prompting researchers to select it, even though its indication and administration route will be different than previously envisaged.
Longitudinal study of the psoriasis - associated skin microbiome
during therapy with ustekinumab in a randomized
Phase 3b
clinical trial — Michael Loesche — Journal of Investigative Dermatology